免疫检查点抑制剂相关胆管炎的研究进展

侯昱丞; 赵洪强; 董草儿; 吴广东; 童翾; 李昂; 卢倩; 陈虹; 汤睿

doi:10.3969/j.issn.1001-5256.2023.02.034

免疫检查点抑制剂相关胆管炎的研究进展

DOI: 10.3969/j.issn.1001-5256.2023.02.034

清华大学附属北京清华长庚医院肝胆胰中心，清华大学临床医学院，北京 102218

基金项目:

国家自然科学基金 (81901957)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：汤睿、侯昱丞、赵洪强对研究的思路及设计有关键贡献；董草儿、吴广东、童翾、李昂参与研究文献的汇总与分析；卢倩、陈虹对论文框架给与关键建议与指导；侯昱丞、赵洪强起草文章关键内容。

详细信息

通信作者:
汤睿，tangrui_hs@163.com(ORCID：0000-0003-3118-3842)

计量
- 文章访问数: 797
- HTML全文浏览量: 852
- PDF下载量: 77
- 被引次数: 0
出版历程
- 收稿日期: 2022-07-03
- 录用日期: 2022-08-18
- 出版日期: 2023-02-20

Research advances in immune checkpoint inhibitor-related cholangitis

Hepatobiliary and Pancreatic Center, Tsinghua University Affiliated Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China

Research funding:

National Natural Science Foundation of China (81901957)

More Information

Corresponding author: TANG Rui, tangrui_hs@163.com (ORCID: 0000-0003-3118-3842)

摘要

摘要: 免疫检查点抑制剂开启了肿瘤治疗的新时代，而免疫治疗相关不良事件是制约其临床应用并逐渐引发关注的重要问题。肝脏是较易受累的靶器官之一。随着研究的进展，学者发现除肝细胞外，肝内外胆管也可成为免疫攻击的对象，继发被称为免疫相关胆管炎的病症。本文通过文献汇总，对免疫检查点抑制剂相关胆管炎的研究进展进行综述，旨在初步揭示其临床、病理、影像特点，为临床早期发现，规范治疗及后续研究提供线索。
- 免疫检查点抑制剂 /
- 免疫相关胆管炎 /
- 程序性死亡蛋白-1
Abstract: Immune checkpoint inhibitors (ICIs) have ushered in a new era of tumor treatment; however, immunotherapy-related adverse events are critical issues that restrict the clinical application of ICIs and have attracted wide attention. The liver is one of the target organs that is easily affected. With the progress in research, scholars have found that besides hepatocytes, intrahepatic and extrahepatic bile ducts can also be attacked by the immune system, leading to the disease known as immune-related cholangitis. This article reviews the research advances in ICI-related cholangitis by summarizing related articles, in order to preliminarily reveal its clinical, pathological, and imaging features and provide clues for early identification, standard treatment, and subsequent research.
- Immune Checkpoint Inhibitors /
- Cholangitis /
- Programmed Death-1

HTML全文

参考文献(41)

[1]	PRIETO LI, BAKER DJ. Cellular Senescence and the Immune system in cancer[J]. Gerontology, 2019, 65(5): 505-512. DOI: 10.1159/000500683.
[2]	COGDILL AP, ANDREWS MC, WARGO JA. Hallmarks of response to immune checkpoint blockade[J]. Br J Cancer, 2017, 117(1): 1-7. DOI: 10.1038/bjc.2017.136.
[3]	BRAHMER JR, LACCHETTI C, SCHNEIDER BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2018, 36(17): 1714-1768. DOI: 10.1200/JCO.2017.77.6385.
[4]	PUZANOV I, DIAB A, ABDALLAH K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group[J]. J Immunother Cancer, 2017, 5(1): 95. DOI: 10.1186/s40425-017-0300-z.
[5]	ANDERSON MA, KURRA V, BRADLEY W, et al. Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography[J]. Br J Radiol, 2021, 94(1118): 20200663. DOI: 10.1259/bjr.20200663.
[6]	HUA YW, ZHAO L. Diagnosis and management of immunotherapy-related liver toxicity[J]. Med J Peking Union Med Coll Hosp, 2021, 12(5): 798-806. DOI: 10.12290/xhyxzz.2021-0138. 华雨薇, 赵林. 免疫治疗相关肝毒性的诊断与管理[J]. 协和医学杂志, 2021, 12(5): 798-806. DOI: 10.12290/xhyxzz.2021-0138.
[7]	GELSOMINO F, VITALE G, D'ERRICO A, et al. Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury[J]. Ann Oncol, 2017, 28(3): 671-672. DOI: 10.1093/annonc/mdw649.
[8]	KAWAKAMI H, TANIZAKI J, TANAKA K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer[J]. Invest New Drugs, 2017, 35(4): 529-536. DOI: 10.1007/s10637-017-0453-0.
[9]	GELSOMINO F, VITALE G, ARDIZZONI A. A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event[J]. Invest New Drugs, 2018, 36(1): 144-146. DOI: 10.1007/s10637-017-0484-6.
[10]	PI B, WANG J, TONG Y, et al. Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management[J]. Eur J Gastroenterol Hepatol, 2021, 33(Suppl 1): e858-e867. DOI: 10.1097/MEG.0000000000002280.
[11]	CHEUNG V, GUPTA T, PAYNE M, et al. Immunotherapy-related hepatitis: real-world experience from a tertiary centre[J]. Frontline Gastroenterol, 2019, 10(4): 364-371. DOI: 10.1136/flgastro-2018-101146.
[12]	MIZUNO K, ITO T, ISHIGAMI M, et al. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies[J]. J Gastroenterol, 2020, 55(6): 653-661. DOI: 10.1007/s00535-020-01677-9.
[13]	KASHIMA J, OKUMA Y, SHIMIZUGUCHI R, et al. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report[J]. Cancer Immunol Immunother, 2018, 67(1): 61-65. DOI: 10.1007/s00262-017-2062-3.
[14]	COHEN JV, DOUGAN M, ZUBIRI L, et al. Liver biopsy findings in patients on immune checkpoint inhibitors[J]. Mod Pathol, 2021, 34(2): 426-437. DOI: 10.1038/s41379-020-00653-1.
[15]	LAKEHAL F, WENDUM D, BARBU V, et al. Phase Ⅰ and phase Ⅱ drug-metabolizing enzymes are expressed and heterogeneously distributed in the biliary epithelium[J]. Hepatology, 1999, 30(6): 1498-1506. DOI: 10.1002/hep.510300619.
[16]	HARADA K, NAKANUMA Y. Biliary innate immunity in the pathogenesis of biliary diseases[J]. Inflamm Allergy Drug Targets, 2010, 9(2): 83-90. DOI: 10.2174/187152810791292809.
[17]	VISENTIN M, LENGGENHAGER D, GAI Z, et al. Drug-induced bile duct injury[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B): 1498-1506. DOI: 10.1016/j.bbadis.2017.08.033.
[18]	FITZGERALD KA, KAGAN JC. Toll-like receptors and the control of immunity[J]. Cell, 2020, 180(6): 1044-1066. DOI: 10.1016/j.cell.2020.02.041.
[19]	HARADA K, ISSE K, NAKANUMA Y. Interferon gamma accelerates NF-kappaB activation of biliary epithelial cells induced by Toll-like receptor and ligand interaction[J]. J Clin Pathol, 2006, 59(2): 184-190. DOI: 10.1136/jcp.2004.023507.
[20]	HARADA K, van de WATER J, LEUNG PS, et al. In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset[J]. Hepatology, 1997, 25(4): 791-796. DOI: 10.1002/hep.510250402.
[21]	HARADA K, ISSE K, SATO Y, et al. Endotoxin tolerance in human intrahepatic biliary epithelial cells is induced by upregulation of IRAK-M[J]. Liver Int, 2006, 26(8): 935-942. DOI: 10.1111/j.1478-3231.2006.01325.x.
[22]	HARADA K, ISSE K, KAMIHIRA T, et al. Th1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis[J]. Hepatology, 2005, 41(6): 1329-1338. DOI: 10.1002/hep.20705.
[23]	GUDNASON HO, BJÖRNSSON HK, GARDARSDOTTIR M, et al. Secondary sclerosing cholangitis in patients with drug-induced liver injury[J]. Dig Liver Dis, 2015, 47(6): 502-507. DOI: 10.1016/j.dld.2015.03.002.
[24]	TAKINAMI M, ONO A, KAWABATA T, et al. Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis[J]. Invest New Drugs, 2021, 39(6): 1716-1723. DOI: 10.1007/s10637-021-01136-z.
[25]	MEKKI A, DERCLE L, LICHTENSTEIN P, et al. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1[J]. Eur J Cancer, 2018, 96: 91-104. DOI: 10.1016/j.ejca.2018.03.006.
[26]	ZEN Y, CHEN YY, JENG YM, et al. Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes[J]. Histopathology, 2020, 76(3): 470-480. DOI: 10.1111/his.14000.
[27]	RASCHI E, MAZZARELLA A, ANTONAZZO IC, et al. Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the FDA adverse event reporting system[J]. Target Oncol, 2019, 14(2): 205-221. DOI: 10.1007/s11523-019-00632-w.
[28]	European Association for the Study of the Liver. EASL clinical practice guideline: Occupational liver diseases[J]. J Hepatol, 2019, 71(5): 1022-1037. DOI: 10.1016/j.jhep.2019.08.008.
[29]	LIM JH. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings[J]. AJR Am J Roentgenol, 2003, 181(3): 819-827. DOI: 10.2214/ajr.181.3.1810819.
[30]	von FIGURA G, STEPHANI J, WAGNER M, et al. Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel[J]. Endoscopy, 2009, 41(Suppl 2): E153- E154. DOI: 10.1055/s-0029-1214707.
[31]	THOMPSON JA, SCHNEIDER BJ, BRAHMER J, et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(4): 387-405. DOI: 10.6004/jnccn.2022.0020.
[32]	SUZMAN DL, PELOSOF L, ROSENBERG A, et al. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents[J]. Liver Int, 2018, 38(6): 976-987. DOI: 10.1111/liv.13746.
[33]	ITO T, ISHIGAMI M, YAMAMOTO T, et al. Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies[J]. Hepatol Int, 2021, 15(5): 1278-1287. DOI: 10.1007/s12072-021-10238-y.
[34]	WANG HP. Adverse reactions associated with immune checkpoint inhibitor in treatment of liver cancer and related treatment measures[J]. J Clin Hepatol, 2022, 38(5): 985-991. DOI: 10.3969/j.issn.1001-5256.2022.05.003. 王汉萍. 肝癌免疫检查点抑制剂治疗相关不良反应及处理[J]. 临床肝胆病杂志, 2022, 38(5): 985-991. DOI: 10.3969/j.issn.1001-5256.2022.05.003.
[35]	SATO K, HAYASHI M, ABE K, et al. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report[J]. Clin J Gastroenterol, 2020, 13(6): 1310-1314. DOI: 10.1007/s12328-020-01178-5.
[36]	DOHERTY GJ, DUCKWORTH AM, DAVIES SE, et al. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury[J]. ESMO Open, 2017, 2(4): e000268. DOI: 10.1136/esmoopen-2017-000268.
[37]	MCCLURE T, CUI W, ASADI K, et al. Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up[J]. BMJ Open Gastroenterol, 2020, 7(1): e000487. DOI: 10.1136/bmjgast-2020-000487.
[38]	OOI R, TOBINO K, SAKABE M, et al. A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis[J]. Respir Med Case Rep, 2020, 31: 101197. DOI: 10.1016/j.rmcr.2020.101197.
[39]	ROMA MG, TOLEDO FD, BOAGLIO AC, et al. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications[J]. Clin Sci (Lond), 2011, 121(12): 523-544. DOI: 10.1042/CS20110184.
[40]	THOMPSON JA, SCHNEIDER BJ, BRAHMER J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(3): 230-241. DOI: 10.6004/jnccn.2020.0012.
[41]	KATAOKA S, MORIGUCHI M, OKISHIO S, et al. Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case[J]. Clin J Gastroenterol, 2022, 15(2): 467-474. DOI: 10.1007/s12328-022-01590-z.